Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001952388 | SCV002207194 | uncertain significance | Renal cell carcinoma | 2021-04-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with MET-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces proline with arginine at codon 865 of the MET protein (p.Pro865Arg). The proline residue is highly conserved and there is a moderate physicochemical difference between proline and arginine. |
Ambry Genetics | RCV004041932 | SCV005037939 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-15 | criteria provided, single submitter | clinical testing | The p.P865R variant (also known as c.2594C>G), located in coding exon 10 of the MET gene, results from a C to G substitution at nucleotide position 2594. The proline at codon 865 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |